A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Public ClinicalTrials.gov record NCT04435431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.
Study identification
- NCT ID
- NCT04435431
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2020
- Primary completion
- Dec 1, 2022
- Completion
- Dec 8, 2022
- Last update posted
- Mar 5, 2024
2020 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Movement Disorders Center of Arizona | Scottsdale | Arizona | 85258 | — |
| Collaborative Neuroscience Research (CNS Research) | Long Beach | California | 90806 | — |
| Parkinson's Disease and Movement Disorders Center of Silicon Valley | Palo Alto | California | 94301 | — |
| Colorado Springs Neurological Associates | Colorado Springs | Colorado | 80907 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| Avantis Clinical Research | Miami | Florida | 33155 | — |
| Elias Research Associates (Allied Biomedical Research Institute) | Miami | Florida | 33155 | — |
| Pharmax Research of South Florida, Inc. | Miami | Florida | 33175 | — |
| Life Medical Research Group Corp | Miami Gardens | Florida | 33014 | — |
| NeuroStudies.net, LLC | Decatur | Georgia | 30030 | — |
| University of Kentucky, Department of Neurology | Lexington | Kentucky | 40536 | — |
| The Movement Disorder Clinic of Oklahoma | Tulsa | Oklahoma | 74136 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Inland Northwest Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04435431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04435431 live on ClinicalTrials.gov.